Diana Do, MD, professor of ophthalmology and vice chair for clinical affairs, Byers Eye Institute, Stanford University, discusses real-world data presented at the American Academy of Ophthalmology showing…
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
The video features an interview with Tien Y. Wong, MD, PhD, Tsinghua University, about a post-hoc analysis from the PULSAR randomized trial evaluating high-dose aflibercept (8 mg) in…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia,…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions.…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
